Atlas Bio Secures $12.5M for AI Drug Trials

Swiss startup Atlas Bio today launched from stealth with a $10 million Seed round led by Creandum, alongside a previously unannounced $2.5 million pre-Seed round. The firm aims to replace expensive Phase II trials and animal studies using an AI model trained on roughly 2 million RNA readouts to simulate patient efficacy and safety before clinical trials begin.